Navigation Links
Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
Date:4/16/2008

tastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding the further development and potential safety, efficacy, regulatory status, commercial potential and other characteristics of Kosan's product candidates; the continuation of current clinical trials; the initiation of additional clinical trials and the timing thereof and the use of Kosan's financial resources. Words such as "will," "expect," "believe," "may," "intend," "plan," "potential" and similar expressions are intended to identify forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Kosan's current expectations. Forward-looking statements involve risks and uncertainties. Kosan's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the uncertain progress and results of Kosan's preclinical and clinical testing, including the risks that studies and trials may not demonstrate safety and efficacy sufficient to initiate cl
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
2. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
3. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
4. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
5. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
6. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
7. Kosan Announces February 28, 2008 Conference Call and Webcast
8. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
9. Kosan Announces Third Quarter 2007 Financial Results
10. Kosan to Reacquire Epothilone Program From Roche
11. Kosan Biosciences to Host Research & Development Day on October 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has filed its Annual Report on Form ... filed Form 20-F includes audited financial statements for the ... can be accessed by visiting the U.S. Securities and ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... 2 to 3 children in 100 are born with a ... but in 80% of the cases scientists do not know ... Katholieke Universiteit Leuven, in collaboration with an Australian research team, ... mental retardation is caused by a twofold production of two ...
... Jan. 24 Cardica, Inc.,(Nasdaq: CRDC ) ... fiscal 2008 second quarter and six months ended ... excellent commercial progress, with over 1,000,C-Port systems shipped ... an expanding,product line designed to enable minimally-invasive cardiac ...
... Defined Structure Synthesized,in the Lab, Team Completes Second ... ROCKVILLE, Md., Jan. 24 A team of 17,researchers ... the largest,man-made DNA structure by synthesizing and assembling the ... This work, published,online today in the journal Science by ...
Cached Biology Technology:Discovery of new cause of mental retardation simplifies search for treatments 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7Venter Institute Scientists Create First Synthetic Bacterial Genome 2Venter Institute Scientists Create First Synthetic Bacterial Genome 3Venter Institute Scientists Create First Synthetic Bacterial Genome 4Venter Institute Scientists Create First Synthetic Bacterial Genome 5Venter Institute Scientists Create First Synthetic Bacterial Genome 6
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... plants supplement the meager diet available from the nutrient-poor ... insects and other small arthropods. Pitcher plants of the ... a simple passive trap but in a paper in ... a biologist and a physicist from the CNRS, working ...
... University center that aims to improve crop production by ... of continued and expanded support from the Monsanto Company, ... will fund student exchanges and a series of plant ... for Plant Molecular Genetics and Agrobiotechnology , a multidisciplinary ...
... emissions from using coal are set to double by 2030, ... global climate change. In view of the essential role of ... where coal is used. The British Geological Survey ... Phase 1 study in Beijing, China today. The aim of this ...
Cached Biology News:Carnivorous plants use pitchers of 'slimy saliva' to catch their prey 2Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center 2UK scientists lead China closer to carbon capture and storage 2
... The TargeTron(TM) Gene Knockout System provides optimized ... specific disruption of bacterial genes by insertion ... the retrohoming ability of group II introns ... re-target the TargeTron group II intron for ...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
... antibody raised against a partial recombinant IFNA2. ... partial recombinant protein is produced in E. coli. ... IU/ mg. OMIM: 147562, ... Lot Number: MM951100564 MA Code: ...
Biology Products: